This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, June 2, 2020 at 8 PM EST.
Date/Time: Tuesday, June 2, 2020 at 8 PM EST
This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T cells. We will feature a panel of leading experts to discuss important topics and considerations surrounding CAR T-cell therapies and the patient populations impacted during this time.
Course Topics:
Associate Professor Section Chief, Indolent Lymphoma Section Chief, New Drug Development Department Lymphoma/Myeloma UT MD Anderson Cancer Center
Matthew Lunning, DO, Associate Professor, Internal Medicine Medical Director, Lymphoma Research Division of Oncology & Hematology University of Nebraska Medical Center
Ahmed Galal, MD, FRACP, MSc,Professor of Medicine Division of Hematologic Malignancies and Cellular Therapy Duke University School of Medicine
Sponsored By:
Eugenio Galli, MD, PhD, on Reexamining Frailty as a Barrier to CAR-T Treatment
June 16th 2025The hematologist at the Hematology and Stem Cell Transplants Unit of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome discussed a study on the effect of comorbidities in patients receiving CAR-T.